Tags Archives: VV ECMO

Perfusfind S.L.

Abstract Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a life-saving therapy for critically ill patients, but it carries an increased risk of thrombosis due to blood interacting with non-physiological surfaces. While..

Perfusfind S.L.

Abstract Unfractionated heparin (UFH) is the most used anticoagulant in patients receiving veno-venous extracorporeal membrane oxygenation (VV-ECMO). Its therapeutic levels are monitored using activated partial thromboplastin time ratio (aPTTr) or..

Perfusfind S.L.

Abstract Importance  Prone positioning may improve outcomes in patients with severe acute respiratory distress syndrome (ARDS), but it is unknown whether prone positioning improves clinical outcomes among patients with ARDS who..

Perfusfind S.L.

Abstract Rationale: Definitive guidelines for anticoagulation management during veno-venous extracorporeal membrane oxygenation (VV ECMO) are lacking, while bleeding complications continue to pose major challenges. Objectives: To describe anticoagulation modalities and..

Perfusfind S.L.

Abstract A restrictive fluid strategy is recommended in patients with acute respiratory distress syndrome (ARDS) managed with venovenous extracorporeal membrane oxygenation (VV ECMO). However, there are no established predictors for..

Perfusfind S.L.

Abstract Mortality prediction for patients with the severe acute respiratory distress syndrome (ARDS) supported with veno-venous extracorporeal membrane oxygenation (VV-ECMO) is challenging. Clinical variables at baseline and on day 3..

Perfusfind S.L.

Abstract Background: Extubation while receiving V-V ECMO is being considered earlier for patients with respiratory failure. This can facilitate early mobilization, participation in physical therapy, and reduce the potential consequences of..

Perfusfind S.L.

Abstract Introduction Most patients on extracorporeal membrane oxygenation (ECMO) decease during therapy on the system. However, the actual causes of death have not been studied sufficiently. This study analyses the..

Perfusfind S.L.

Abstract Background: Hospitalized COVID-19 patients with hypoxemic respiratory failure may deteriorate despite invasive mechanical ventilation and thus require extracorporeal membrane oxygenation (ECMO) support. Unfractionated heparin (UFH) is the antithrombotic of..

Perfusfind S.L.

Abstract Obesity is associated with an overall increased risk of morbidity and mortality. However, in patients with critical illness, sepsis, and acute respiratory distress syndrome, obesity may be protective, termed..

Perfusfind S.L.

Abstract Introduction and Methods We examined the relationship between 24-h pre- and post-cannulation arterial oxygen tension (PaO2) and arterial carbon dioxide tension (PaCO2) and subsequent acute brain injury (ABI) in..

Perfusfind S.L.

Abstract Purpose Ultraprotective ventilation in  (ARDS) patients with veno-venous  (VV ECMO) reduces mechanical power (MP) through changes in positive end-expiratory pressure (PEEP); however, the optimal approach to titrate PEEP is unknown. This..

Perfusfind S.L.

This case reports on a 41-years old male with no significant medical history who was admitted to the emergency room following 25% total body surface area (TBSA) deep partial thickness..

Perfusfind S.L.

Abstract Objective:  Analysis of the prevalence and risk factors for weaning failure from venovenous extracorporeal membrane oxygenation (VV-ECMO) in patients with severe acute respiratory insufficiency. Design:  Single-center retrospective observational study. Setting:  Sixteen beds medical ICU at the University..

Perfusfind S.L.

Abstract Background Extracorporeal membrane oxygenation (ECMO) is a recognized method of support in patients with severe and refractory acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 infection. While veno-venous (VV)..

Perfusfind S.L.

Abstract Patients with respiratory failure may remain hypoxemic despite treatment with venovenous extracorporeal membrane oxygenation (VV-ECMO). Therapeutic hypothermia is a potential treatment for such hypoxia as it reduces cardiac output (�˙�) and oxygen consumption. We modified a previously..

Perfusfind S.L.

Abstract Mechanical ventilation for respiratory failure due to COVID-19 is associated with significant morbidity and mortality. Veno-venous extracorporeal membrane oxygenation (ECMO) is an attractive management option. This study sought to determine the effect..

Perfusfind S.L.

Abstract Severe acute refractory respiratory failure is considered a life-threatening situation, with a high mortality of 40 to 60%. When conservative oxygenation methods fail, a lifesaving measure is the introduction..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation (ECMO) is used in critically ill patients with severe pulmonary and/or cardiac failure. Blood is drained from the venous system and pumped through a membrane oxygenator..

Perfusfind S.L.

Abstract Background: This study aimed to determine the optimal position of venovenous extracorporeal membrane oxygenation (V-V ECMO) draining cannulas for refractory respiratory failure based on short-term clinical results. Methods: In total, 278..

Perfusfind S.L.

Abstract Objective:  To determine the association of venovenous extracorporeal membrane oxygenation (VV-ECMO) initiation with changes in vasoactive-inotropic scores (VISs) in children with pediatric acute respiratory distress syndrome (PARDS) and cardiovascular instability. Design:  Retrospective cohort..

Perfusfind S.L.

Abstract Background A strategy that limits tidal volumes and inspiratory pressures, improves outcomes in patients with the acute respiratory distress syndrome (ARDS). Extracorporeal carbon dioxide removal (ECCO2R) may facilitate ultra-protective ventilation...

Perfusfind S.L.

Abstract Background: The use of veno-venous extracorporeal membrane oxygenation (VV ECMO) remains controversial in trauma patients with acute respiratory distress syndrome (ARDS). Here, we aimed to investigate the therapeutic benefits..

Perfusfind S.L.

Abstract Background Mobilization is important in longer courses in intensive care unit (ICU), typical for patients requiring venovenous extracorporeal membrane oxygenation (V-V ECMO). For patients supported with ECMO, especially out-of-bed..

Perfusfind S.L.

Abstract Background Safe and timely liberation from veno-venous extracorporeal membrane oxygenation (V-V ECMO) would be expected to reduce the duration of ECMO, the risk of complications, and costs. However, how..

Perfusfind S.L.

Impact of Drainage Cannula Size and Blood Flow Rate on the Outcome of Patients Receiving Venovenous ECMO for ARDS: An ELSO Registry Analysis

Perfusfind S.L.

Abstract Patients receiving venovenous extracorporeal membrane oxygenation (VV-ECMO) often require extended periods of ventilation. We examined the role of tracheostomy on outcomes of patients supported with VV-ECMO. We reviewed all patients at our institution..

Perfusfind S.L.

Abstract Objectives: The CytoSorb therapy in COVID-19 (CTC) registry evaluated the clinical performance and treatment parameters of extracorporeal hemoadsorption integrated with veno-venous extracorporeal membrane oxygenation (VV ECMO) in critically ill COVID-19..

Perfusfind S.L.

Abstract Background Despite the demonstrated benefits of rehabilitation, active physical therapy and early mobilization are not universally performed during critical illness, especially among patients receiving extracorporeal membrane oxygenation (ECMO), with..

Perfusfind S.L.

Abstract In this retrospective observational cohort study, we aimed to describe the rate of extracorporeal membrane oxygenation (ECMO) circuit change, the associated risk factors and its relationship with patient characteristics and outcome..